Journal article
The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
Abstract
BACKGROUND: Sunitinib is administered on a rigid schedule that may not be optimal for all patients. We hypothesised that toxicity-driven dose and schedule changes would optimise drug exposure and outcome for each patient.
MATERIALS AND METHODS: In a phase 2 trial, 117 patients with metastatic clear cell renal cell cancer were started on sunitinib 50 mg/day with the aim to treat for 28 days. Treatment breaks were reduced to 7 days. Sunitinib …
Authors
Bjarnason GA; Knox JJ; Kollmannsberger CK; Soulieres D; Ernst DS; Zalewski P; Canil CM; Winquist E; Hotte SJ; North SA
Journal
European Journal of Cancer, Vol. 108, , pp. 69–77
Publisher
Elsevier
Publication Date
February 2019
DOI
10.1016/j.ejca.2018.12.006
ISSN
0959-8049
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAged, 80 and overAntineoplastic AgentsBone NeoplasmsCarcinoma, Renal CellDose-Response Relationship, DrugDrug Administration ScheduleDrug-Related Side Effects and Adverse ReactionsDuration of TherapyFeasibility StudiesFemaleHumansKidney NeoplasmsLiver NeoplasmsLung NeoplasmsMaleMiddle AgedPatient Reported Outcome MeasuresProgression-Free SurvivalSunitinibSurvival Rate